Creative Planning Brainstorm Cell Therapeutics Inc. Transaction History

Creative Planning

$101 Billion
Q3 2024

A detailed history of Creative Planning transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Creative Planning holds 13,846 shares of BCLI stock, worth $31,568. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,846

Previous 20,926 33.83%

Holding current value

$31,568

Previous $7,000 57.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 11, 2024	SELL	$0.22 - $0.42 $1,557 - $2,973	-7,080 Reduced 33.83%	13,846 $3,000
Q2 2024 Aug 15, 2024	SELL	$0.34 - $0.74 $272 - $592	-800 Reduced 3.68%	20,926 $7,000
Q1 2024 May 10, 2024	BUY	$0.28 - $0.66 $198 - $468	710 Added 3.38%	21,726 $12,000
Q4 2023 Feb 14, 2024	BUY	$0.15 - $0.4 $731 - $1,951	4,878 Added 30.23%	21,016 $5,000
Q2 2023 Jul 21, 2023	BUY	$2.0 - $3.2 $4,292 - $6,867	2,146 Added 15.34%	16,138 $33,000
Q1 2023 May 15, 2023	SELL	$1.43 - $3.3 $16,715 - $38,573	-11,689 Reduced 45.52%	13,992 $46,000
Q4 2022 Feb 10, 2023	SELL	$1.37 - $4.42 $6,850 - $22,100	-5,000 Reduced 16.3%	25,681 $42,000
Q3 2022 Nov 03, 2022	BUY	$2.55 - $4.42 $78,236 - $135,610	30,681 New	30,681 $136,000
Q1 2021 Apr 30, 2021	SELL	$3.46 - $7.88 $125,258 - $285,271	-36,202 Closed	0 $0
Q4 2020 Jan 29, 2021	BUY	$3.99 - $17.73 $40,698 - $180,846	10,200 Added 39.23%	36,202 $164,000
Q3 2020 Nov 05, 2020	SELL	$11.19 - $16.92 $55,950 - $84,600	-5,000 Reduced 16.13%	26,002 $440,000
Q2 2020 Jul 23, 2020	BUY	$4.42 - $12.66 $137,028 - $392,485	31,002 New	31,002 $348,000

Others Institutions Holding BCLI

# of Institutions

Shares Held

10.8M

Call Options Held

160K

Put Options Held

30.5K

View Full List

About BRAINSTORM CELL THERAPEUTICS INC.

Ticker BCLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,486,200
Market Cap $83.2M
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...

More about BCLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account

Creative Planning Brainstorm Cell Therapeutics Inc. Transaction History